Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

  1. Home

  • Sunday, Oct 26th
    9:00 AM - 10:30 AM Central Time
    26S11: 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus
    Location: W196A-C
    Moderator: Bonnie Bermas, MD – UTSouthwestern.edu
    Moderator: Jennifer Grossman, MD – UCLA
    Moderator: Maria Dall'Era, MD – UCSF
    Moderator: Mary Beth Son, MD – Boston Children's Hospital
    Session Coordinator: Grant Louie, MD, MHS – Arthritis and Rheumatism Associates, PC
    Session Coordinator: Anca Askanase, MD, MPH – Columbia University Medical Center
    Session Coordinator: May Choi, MD, FRCPC, MPH – University of Calgary
    Session Coordinator: Jennifer Grossman, MD – UCLA
     CE: 1.50
  • Sunday, Oct 26th
    9:00 AM - 9:15 AM Central Time
    ACR Extrarenal SLE Guideline Development and Key Recommendations
    Location: W196A-C
    Speaker: Lisa Sammaritano, MD – Hospital for Special Surgery
  • Sunday, Oct 26th
    9:15 AM - 9:30 AM Central Time
    Applying the Guidelines to Treat Lupus Serositis
    Location: W196A-C
    Speaker: Ali Duarte-Garcia, MD, MSc – Mayo Clinic
  • Sunday, Oct 26th
    9:30 AM - 9:45 AM Central Time
    Applying the Guideline to Treat Cutaneous Lupus
    Location: W196A-C
    Speaker: Victoria Werth, MD – University of Pennsylvania
  • Sunday, Oct 26th
    9:45 AM - 10:00 AM Central Time
    Applying the Guideline to Treat Lupus Arthritis
    Location: W196A-C
    Speaker: Anca Askanase, MD, MPH – Columbia University Medical Center
  • Sunday, Oct 26th
    10:00 AM - 10:20 AM Central Time
    Applying the Guideline to Treat Child-hood Onset Lupus: Pediatric and Adult Rheumatology Perspectives
    Location: W196A-C
    Speaker: Linda Hiraki, MD, FRCPC, ScD – The Hospital for Sick Children
  • Sunday, Oct 26th
    10:20 AM - 10:30 AM Central Time
    Guidelines Q & A
    Location: W196A-C
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Treatment Poster I
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0593: Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Dag Leonard, MD, PhD – Uppsala University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0594: Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
    Location: Hall F1
    Abstract Poster Presenter: Dag Leonard, MD, PhD – Uppsala University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0595: Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
    Location: Hall F1
    Abstract Poster Presenter: Eric Morand, MD, PhD – Monash University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0596: Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
    Location: Hall F1
    Abstract Poster Presenter: Guillermo Pons-Estel, MD, PhD – CREAR
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0598: Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
    Location: Hall F1
    Abstract Poster Presenter: Nirali Sanghavi, MBBS – Westchester Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0599: Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0600: Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
    Location: Hall F1
    Abstract Poster Presenter: Ahlam Almarzooqi, MD – Emirates Health Services
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0601: Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
    Location: Hall F1
    Abstract Poster Presenter: Ali Ardekani, MD, MSc – Mayo Clinic
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0602: Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
    Location: Hall F1
    Abstract Poster Presenter: Ami Vyas, PhD – University of Rhode Island
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0603: Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
    Location: Hall F1
    Abstract Poster Presenter: Amir Daneshvar, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0604: Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Antonio Aznar-Esquivel, MD – Servicio Canario de Salud
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0605: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
    Location: Hall F1
    Abstract Poster Presenter: Anubhav Singh, MD – Baptist hospital of southeast Texas
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0606: Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
    Location: Hall F1
    Abstract Poster Presenter: Arielle Mendel, MD, FRCPC, MSc – McGill University Health Centre
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0607: Age at Diagnosis of SLE Has Increased in a United States Longitudinal Cohort
    Location: Hall F1
    Abstract Poster Presenter: Daniel Goldman, PhD – Johns Hopkins University School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0608: Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
    Location: Hall F1
    Abstract Poster Presenter: Elena Heras Recuero, MD – Hospital Fundacion Jimenez Dias
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0609: Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Eleni Papachristodoulou, MD – Mount Auburn Hospital, Harvard Medical School
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0610: The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Emma Trachman, MD – Duke University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0611: Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0612: Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
    Location: Hall F1
    Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0614: Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
    Location: Hall F1
    Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0615: Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
    Location: Hall F1
    Abstract Poster Presenter: Jacob Klein, MD – Ohio State University Wexner Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0618: Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
    Location: Hall F1
    Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0619: Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
    Location: Hall F1
    Abstract Poster Presenter: Luciana Seguro, MD, PhD – Hospital das Clínicas HCFMUSP, University of Sao Paulo
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0620: The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
    Location: Hall F1
    Abstract Poster Presenter: Luis Fajardo Hermosillo, MD, MSc (he/him/his) – Universidad de Guadalajara RFC UGU250907MH5
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0621: Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
    Location: Hall F1
    Abstract Poster Presenter: LUIS CAJAS, Sr, MD, MSc – universidad nacional de colombia
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0622: Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Malvika Gupta, MD (she/her/hers) – Mayo Clinic
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0623: Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
    Location: Hall F1
    Abstract Poster Presenter: Marco Martinez, MD – Mayo Clinic
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0624: Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria
    Location: Hall F1
    Abstract Poster Presenter: Matthew Dapas, PhD – Northwestern University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0625: DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
    Location: Hall F1
    Abstract Poster Presenter: Meghan Nelson, DO – National Institutes of Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0626: Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
    Location: Hall F1
    Abstract Poster Presenter: Nalani Sachan, PhD – NYU Grossman School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0627: Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
    Location: Hall F1
    Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0628: Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0630: Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Ranjan Gupta, MD, DM (he/him/his) – All India Institute of Medical Sciences
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0632: Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Rusudan Tskitishvili, MD – Virtua Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0633: Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis
    Location: Hall F1
    Abstract Poster Presenter: Sai Shanmukha Sreeram Pannala, MD (he/him/his) – Northwell Health/Staten Island University Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0634: Association of Lifestyle and Integrative Health Practices with Health-related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
    Location: Hall F1
    Abstract Poster Presenter: Sarah Lieber, MD, MS – Hospital for Special Surgery
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0635: Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Sarah Lieber, MD, MS – Hospital for Special Surgery
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0637: DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
    Location: Hall F1
    Abstract Poster Presenter: Sundus Dwidar, B.S. – National Institutes of Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0638: Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
    Location: Hall F1
    Abstract Poster Presenter: Takehiro Nakai, MD – St. Luke's International Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0639: Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
    Location: Hall F1
    Abstract Poster Presenter: Vanesa Calvo Río, MD – Hospital Universitario Marqués de Valdecilla, Immunopathology group, IDIVAL
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0640: Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
    Location: Hall F1
    Abstract Poster Presenter: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0641: Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease - data from the CASTLE Phase I/II basket study
    Location: Hall F1
    Abstract Poster Presenter: Georg Schett, MD – Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0642: Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
    Location: Hall F1
    Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0644: Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
    Location: Hall F1
    Abstract Poster Presenter: Joan Merrill, MD – Oklahoma Medical Research Foundation
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0645: Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-week Results from a Phase 3 Trial
    Location: Hall F1
    Abstract Poster Presenter: Maria Dall'Era, MD – UCSF
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0646: A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
    Location: Hall F1
    Abstract Poster Presenter: Qiubai Li, MD – Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0647: anti-cd19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: An Open-label Pilot Study
    Location: Hall F1
    Abstract Poster Presenter: Rong Mu, n/a – Peking University Third Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0648: Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Sarah Al Qassimi, MD – Cleveland Clinic Abu Dhabi
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0649: Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
    Location: Hall F1
    Abstract Poster Presenter: Terry Yan, -None- – GSK
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0650: Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
    Location: Hall F1
    Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0651: The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0652: Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
    Location: Hall F1
    Abstract Poster Presenter: Brandon Jackson, MPH – Lupus Therapeutics
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0653: In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens
    Location: Hall F1
    Abstract Poster Presenter: Chantal Tasset, PhD – Galapagos NV
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0654: Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
    Location: Hall F1
    Abstract Poster Presenter: Ed Vital, MD – University of Leeds
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0655: Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
    Location: Hall F1
    Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0656: Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
    Location: Hall F1
    Abstract Poster Presenter: Fangfang Sun, MD – Renji Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0657: Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
    Location: Hall F1
    Abstract Poster Presenter: FNU Ruchi, MD – SUNY Upstate Medical University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0659: Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
    Location: Hall F1
    Abstract Poster Presenter: Ivette Casafont-Sole, MD – Hospital Universitari Germans Trias i Pujol
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0660: Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
    Location: Hall F1
    Abstract Poster Presenter: J. Michelle Kahlenberg, MD, PhD – University of Michigan
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0661: Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry
    Location: Hall F1
    Abstract Poster Presenter: Leanna Wise, MD, MPH – LAGMC/Keck Medicine of USC
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0662: Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
    Location: Hall F1
    Abstract Poster Presenter: Marta Mosca, MD;PhD – University of Pisa
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0663: iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
    Location: Hall F1
    Abstract Poster Presenter: Parastoo Fazeli, MD (she/her/hers) – UMN
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0664: Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
    Location: Hall F1
    Abstract Poster Presenter: Richard Furie, MD – Northwell
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0665: Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
    Location: Hall F1
    Abstract Poster Presenter: Richard Furie, MD – Northwell
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0666: Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
    Location: Hall F1
    Abstract Poster Presenter: Sarah Crisci, MS, MPH – Thermo Fisher Scientific
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0667: Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
    Location: Hall F1
    Abstract Poster Presenter: Sawyer May, BA – Spherix Global Insights
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0668: Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Takeshi Suzuki, n/a (he/him/his) – St. Marianna University School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0669: Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
    Location: Hall F1
    Abstract Poster Presenter: Youngmin Kim, MD – Brigham and Women's Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0670: Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
    Location: Hall F1
    Abstract Poster Presenter: Zahraa Qamhieh, MBBS, MMSc – University of Wisconsin Madison
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0613: A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights from an Inception Cohort
    Location: Hall F1
    Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0616: Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
    Location: Hall F1
    Abstract Poster Presenter: Juliana Silvatti, MMSc (she/her/hers) – Universidade Federal de São Paulo
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0631: Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow up in an Inception Cohort of SLE (INSPIRE) from India
    Location: Hall F1
    Abstract Poster Presenter: Rudrarpan Chatterjee, MD, MBBS, DM – Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow.
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0636: AA Novel Kidney-specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease Through Distinct Molecular Pathways Novel Kidney-specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease Through Distinct Molecular Pathways
    Location: Hall F1
    Abstract Poster Presenter: Sepehr Taghavi, MSc – Exagen Inc
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0597: Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0617: Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
    Location: Hall F1
    Abstract Poster Presenter: Kathryn Counts, BS (she/her/hers) – Medical University of South Carolina
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0629: Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
    Location: Hall F1
    Abstract Poster Presenter: Pankti Mehta, MD, MBBS, DM – University of Toronto
  • Sunday, Oct 26th
    1:00 PM - 2:30 PM Central Time
    26S30: Abstracts: Systemic Lupus Erythematosus – Treatment I
    Location: S103
    Abstract Moderator: Cristina Arriens, MD, MS – Oklahoma Medical Research Foundation
    Abstract Moderator: Amit Saxena, MD, MSc – NYU Grossman School of Medicine
     CE: 0.00
  • Sunday, Oct 26th
    1:00 PM - 1:15 PM Central Time
    0801: Achieving Sustained Lupus Low Disease Activity State and Remission with Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase II Study
    Location: S103
    Presenting Author: Ed Vital, MD – University of Leeds
  • Sunday, Oct 26th
    1:15 PM - 1:30 PM Central Time
    0802: Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
    Location: S103
    Presenting Author: Eric Morand, MD, PhD – Monash University
  • Sunday, Oct 26th
    1:30 PM - 1:45 PM Central Time
    0803: Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
    Location: S103
    Presenting Author: Mariele Gatto, MD – University of Turin
  • Sunday, Oct 26th
    1:45 PM - 2:00 PM Central Time
    0804: Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
    Location: S103
    Presenting Author: Grace Haeun Lee, BA – Massachusetts General Hospital
  • Sunday, Oct 26th
    2:00 PM - 2:15 PM Central Time
    0805: Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis
    Location: S103
    Presenting Author: Jacquelyn Nestor, MD, PhD – Massachusetts General Hospital
  • Sunday, Oct 26th
    2:15 PM - 2:30 PM Central Time
    0806: Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
    Location: S103
    Presenting Author: Teng-Chieh Hsu, MD – Wuri Lin Shin Hospital
  • Sunday, Oct 26th
    3:00 PM - 4:00 PM Central Time
    26S60: Edmund Dubois Memorial Lecture
    Location: W375A
    Moderator: Keith Elkon, MD – University of Washington
    Session Coordinator: Gregory Gardner, MD – University of Washington
     CE: 1.00
  • Sunday, Oct 26th
    3:00 PM - 4:00 PM Central Time
    Dubois' Legacy: B Cell Mechanisms and Targeted Interventions in Lupus Nephritis
    Location: W375A
    Speaker: Shaun Jackson, MD, PhD – Seattle Children's Research Institute
  • Sunday, Oct 26th
    3:00 PM - 4:30 PM Central Time
    26S70: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis
    Location: S102
    Abstract Moderator: Yashaar Chaichian, MD – Stanford University
    Abstract Moderator: Konstantinos Tselios, MD, PhD – McMaster University
     CE: 0.00
  • Sunday, Oct 26th
    3:00 PM - 3:15 PM Central Time
    0837: Risk of New Proteinuria in Next Ten Years in SLE
    Location: S102
    Presenting Author: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
  • Sunday, Oct 26th
    3:15 PM - 3:30 PM Central Time
    0838: Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
    Location: S102
    Presenting Author: Brad Rovin, MD – The Ohio State University
  • Sunday, Oct 26th
    3:30 PM - 3:45 PM Central Time
    0839: Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
    Location: S102
    Presenting Author: Iris Tang, MBBS, MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
  • Sunday, Oct 26th
    3:45 PM - 4:00 PM Central Time
    0840: Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
    Location: S102
    Presenting Author: Andrea Fava, MD – Johns Hopkins University
  • Sunday, Oct 26th
    4:00 PM - 4:15 PM Central Time
    0841: Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
    Location: S102
    Presenting Author: Kinga Grzybowski, MD – Jefferson Einstein Montgomery Hospital
  • Sunday, Oct 26th
    4:15 PM - 4:30 PM Central Time
    0842: Association of Urinary Biomarkers with Histological Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Lupus Nephritis
    Location: S102
    Presenting Author: Andrea Fava, MD – Johns Hopkins University
  • Monday, Oct 27th
    10:30 AM - 11:30 AM Central Time
    27M31: Rheumatology Research Foundation Memorial Lecture: To Memoralize Dr. Eng Tan
    Location: W375B
    Moderator: May Choi, MD, FRCPC, MPH – University of Calgary
    Session Coordinator: Gregory Gardner, MD – University of Washington
     CE: 1.00
  • Monday, Oct 27th
    10:30 AM - 11:30 AM Central Time
    From Antibodies to Cells: Unraveling the Complexities of Systemic Lupus Erythematosus
    Location: W375B
    Speaker: George Tsokos, MD – BIDMC
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Animal Models Poster
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Treatment Poster II
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0934: The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
    Location: Hall F1
    Abstract Poster Presenter: Arielle Glatman Zaretsky, PhD – Regeneron
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0935: Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Cecilia Stumpf, BA – Northwestern University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0936: Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
    Location: Hall F1
    Abstract Poster Presenter: Chaim Putterman, MD – Albert Einstein College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0937: MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
    Location: Hall F1
    Abstract Poster Presenter: Chaim Putterman, MD – Albert Einstein College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0938: Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
    Location: Hall F1
    Abstract Poster Presenter: Chaim Putterman, MD – Albert Einstein College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0939: Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Chengfeng Xue, PhD (he/him/his) – WuXi AppTec
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0940: Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling
    Location: Hall F1
    Abstract Poster Presenter: Chirag Raparia, PhD, MS, BS (he/him/his) – Donald and Barbara Zucker School of Medicine At Hofstra/Northwell
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0941: In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
    Location: Hall F1
    Abstract Poster Presenter: Isin Dalkilic-Liddle, PhD – Orna Therapeutics
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0942: Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
    Location: Hall F1
    Abstract Poster Presenter: Jennifer Nicholson, BS (she/her/hers) – University of Rochester
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0943: Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
    Location: Hall F1
    Abstract Poster Presenter: Jeremy Tilstra, MD, PhD – University of Pittsburgh
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0944: L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis
    Location: Hall F1
    Abstract Poster Presenter: Jim Oates, MD – Medical University of South Carolina
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0945: Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
    Location: Hall F1
    Abstract Poster Presenter: Jorge Romo-Tena, MD, PhD – NIH
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0946: A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
    Location: Hall F1
    Abstract Poster Presenter: Juan Liang, DrPH – Gempharmatech
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0947: Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
    Location: Hall F1
    Abstract Poster Presenter: Kaitlin Carroll, PhD – Institute of Molecular Medicine, The Feinstein Institutes for Medical Research
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0948: Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease
    Location: Hall F1
    Abstract Poster Presenter: Lance Peterson, MD, PhD – Washington University in St Louis
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0949: The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
    Location: Hall F1
    Abstract Poster Presenter: Mehrnaz Gharaee-Kermani, DVM, MPH, PhD – University of Michigan
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0950: Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
    Location: Hall F1
    Abstract Poster Presenter: mingyang zhang, n/a (he/him/his) – Daping Hospital, Army Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0951: Epidermal IFNκ Increases Circulating and Cutaneous Monocytes in a C57/Bl6 Overexpression Mouse Model
    Location: Hall F1
    Abstract Poster Presenter: Patrick O'Brien, BS (he/him/his) – University of Michigan
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0952: Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus
    Location: Hall F1
    Abstract Poster Presenter: Rachael Werner, MD, PhD – Medical University of South Carolina
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    0953: NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
    Location: Hall F1
    Abstract Poster Presenter: Rachel Weissman-Tsukamoto, BS, MAT – Feinstein Institute of Molecular Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1467: Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1468: A Hipaa-compliant LLM for Personalized Therapeutic Decision-making in Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Abhimanyu Amarnani, MD, PhD – New York University Grossman School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1469: Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Adriana Vázquez, Sr, MD (she/her/hers) – Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1470: Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
    Location: Hall F1
    Abstract Poster Presenter: Ali Rizvi, MS, BS (he/him/his) – Georgetown University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1471: Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Amir Daneshvar, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1472: Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
    Location: Hall F1
    Abstract Poster Presenter: Liza Rajasekhar, MBBS , MD (she/her/hers) – Nizam's Institute of Medical Sciences
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1473: Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Anika Morgado, MD (she/her/hers) – Vanderbilt University Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1474: Rethinking Heart Risk Prediction for Lupus Patients
    Location: Hall F1
    Abstract Poster Presenter: Aretha On, BS – Perelman School of Medicine, University of Pennsylvania
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1475: Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Arielle Mendel, MD, FRCPC, MSc – McGill University Health Centre
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1476: Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-analysis of Prevalence and Clinical Correlates
    Location: Hall F1
    Abstract Poster Presenter: Bana Shawareb, MD (she/her/hers) – Cleveland Clinic Akron General
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1477: Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
    Location: Hall F1
    Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1478: Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Bin zhou, MD – The First School of Clinical Medicine, Southern Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1479: Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
    Location: Hall F1
    Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1480: Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
    Location: Hall F1
    Abstract Poster Presenter: Chen-Yu Lee, MD – Johns Hopkins University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1481: Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
    Location: Hall F1
    Abstract Poster Presenter: Divya Sudireddy, MBBS – Boston Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1482: Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
    Location: Hall F1
    Abstract Poster Presenter: Erik Cimé-Aké, n/a – Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1483: Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
    Location: Hall F1
    Abstract Poster Presenter: Fernanda Massiel Garcia Garcia, MD (she/her/hers) – Hospital Universitario "Dr. José Eleuterio González" UANL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1484: Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
    Location: Hall F1
    Abstract Poster Presenter: Freya Shah, MD (she/her/hers) – NYMC/Landmark Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1485: Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index
    Location: Hall F1
    Abstract Poster Presenter: Guru Vijay Chagalakondu, DM – Employee State Insurance Corporation (ESIC)
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1486: Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
    Location: Hall F1
    Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1487: Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
    Location: Hall F1
    Abstract Poster Presenter: Jennifer Rogers, MD – Duke
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1488: Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Jessica Dai, BS – New York University Grossman School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1489: Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: José M. Bretón, MD (he/him/his) – University of Puerto Rico
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1490: Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
    Location: Hall F1
    Abstract Poster Presenter: Judith Hernández Sánchez, MBBS, MEd – Universidad de Las Palmas de Gran Canaria
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1491: Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
    Location: Hall F1
    Abstract Poster Presenter: Julián Barahona-Correa, MD – Stanford University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1492: Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Katherine Moseley, BS (she/her/hers) – Medical University of South Carolina
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1493: Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
    Location: Hall F1
    Abstract Poster Presenter: Lilliana Serrano Arroyo, MD, MPH – University of Puerto Rico Medical Sciences Campus
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1494: Comparing Childhood-Onset Versus Adult-Onset Systemic Lupus Erythematosus Young Adults’ Lived Employment Experiences
    Location: Hall F1
    Abstract Poster Presenter: Lily Lim, MD, PhD – University of Manitoba
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1495: Comparing the 0-10 Physician Global Assessment Scale to Categorical Disease Activity States among Pediatric Patients with SLE
    Location: Hall F1
    Abstract Poster Presenter: Livie Timmerman Blackmon, MPH, CCRC – University of Alabama at Birmingham
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1496: Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
    Location: Hall F1
    Abstract Poster Presenter: Manikandan Gopal, DM – Christian Medical College Vellore
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1497: Acute Care Utilization in Patients with Antiphospholipid Syndrome And/or Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Megan Barber, MD, PhD – University of Calgary
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1498: Both Race and Socioeconomic Status Affect Mortality in SLE
    Location: Hall F1
    Abstract Poster Presenter: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1499: Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1500: Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
    Location: Hall F1
    Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1501: Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes - Results from Real World Data
    Location: Hall F1
    Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1502: Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1503: Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
    Location: Hall F1
    Abstract Poster Presenter: Ranjan Gupta, MD, DM (he/him/his) – All India Institute of Medical Sciences
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1504: High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
    Location: Hall F1
    Abstract Poster Presenter: Richard Oppong, PhD – NATIONAL INSTITUTES OF HEALTH
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1505: Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
    Location: Hall F1
    Abstract Poster Presenter: Romy Kallas, MD, MS – Hospital for Special Surgery
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1506: Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
    Location: Hall F1
    Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1507: Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
    Location: Hall F1
    Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1508: Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
    Location: Hall F1
    Abstract Poster Presenter: Sheila Serin, MD – Ochsner Clinic Foundation
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1509: Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
    Location: Hall F1
    Abstract Poster Presenter: Shuzo Sato, MD, PhD (he/him/his) – Fukushima Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1510: Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Sitian Zang, n/a – Department of Rheumatology and Immunology, Peking University People’s Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1511: Mental Health and Medical Burden:  The Impact of Depression on Length of Stay in Lupus Patients
    Location: Hall F1
    Abstract Poster Presenter: Sophia Chang Stauffer, MPH – Mount Sinai Hospital, Sinai Urban Health Institute and Univ.of Illinois @ Chicago, Dept Medicine, Div. Endocrinology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1512: anti-u1-rnp Antibody Positivity Is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
    Location: Hall F1
    Abstract Poster Presenter: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1513: Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
    Location: Hall F1
    Abstract Poster Presenter: Ufuoma Mamoh, MBChB – Medstar Georgetown University (Baltimore) Internal Medicine Residency
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1514: Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Yan Wang, n/a (she/her/hers) – Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1515: Machine Learning–defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
    Location: Hall F1
    Abstract Poster Presenter: Yuke Hou, MD – Peking University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1517: The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
    Location: Hall F1
    Abstract Poster Presenter: Aijing Liu, PhD – Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1518: Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
    Location: Hall F1
    Abstract Poster Presenter: Ali Ali, MD, RhMSUS – Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1519: Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
    Location: Hall F1
    Abstract Poster Presenter: Anca Askanase, MD, MPH – Columbia University Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1520: Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Bahtiyar Toz, MD – Zucker School of Medicine at Hofstra/ Northwell
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1521: Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
    Location: Hall F1
    Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1522: Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
    Location: Hall F1
    Abstract Poster Presenter: Carlos Pena, MD – Jefferson Einstein Philadelphia
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1523: Genetic architecture and translational insights for SLE progression from preclinical stages
    Location: Hall F1
    Abstract Poster Presenter: Dajiang Liu, Distinguished Professor – Penn State College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1524: Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: David Karp, MD, PhD, MACR – UT Southwestern Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1525: Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
    Location: Hall F1
    Abstract Poster Presenter: Ed Vital, MD – University of Leeds
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1526: Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
    Location: Hall F1
    Abstract Poster Presenter: Ed Vital, MD – University of Leeds
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1527: Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
    Location: Hall F1
    Abstract Poster Presenter: Egla Sanchez-Peralta, MS (she/her/hers) – Universidad Autonoma de Nuevo Leon
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1528: Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Esteban Caleb Garza González, MD (he/him/his) – Facultad de Medicina, Universidad Autónoma de Nuevo León
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1529: Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
    Location: Hall F1
    Abstract Poster Presenter: Georg Schett, MD – Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1530: The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Guillermo Pons-Estel, MD, PhD – CREAR
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1531: Achieving Remission and Low Disease Activity with Belimumab versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
    Location: Hall F1
    Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1532: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Jan Davidson-Moncada, PhD, MBBS – Bioheng
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1533: Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
    Location: Hall F1
    Abstract Poster Presenter: Jeff Ellis, PharmD, MS – GSK
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1534: Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
    Location: Hall F1
    Abstract Poster Presenter: Jeff Ellis, PharmD, MS – GSK
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1535: INB-619 - A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases
    Location: Hall F1
    Abstract Poster Presenter: Lawrence Lamb, Jr, PhD – IN8bio, Inc.
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1536: Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
    Location: Hall F1
    Abstract Poster Presenter: Aarat Patel, MD – GSK, US Medical Affairs
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1537: Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
    Location: Hall F1
    Abstract Poster Presenter: Melanie Hagen, MD (she/her/hers) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1538: Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
    Location: Hall F1
    Abstract Poster Presenter: Minoru Hasegawa, MD;PhD – Division of Medicine, University of Fukui
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1539: The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
    Location: Hall F1
    Abstract Poster Presenter: Muhammad Usman Hashmi, MD, MBBS – Nishtar Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1540: WITHDRAWN
    Location: Hall F1
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1541: Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
    Location: Hall F1
    Abstract Poster Presenter: Qizhi Yuan, PhD – Peking Union Medical College
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial
    Location: Hall F1
    Abstract Poster Presenter: Richard Furie, MD – Northwell
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1543: Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Sila Mateo Faxas, MD (she/her/hers) – Good Samaritan Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1544: Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Sri Laxmi Priya Sunkara, MD (she/her/hers) – White river medical center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
    Location: Hall F1
    Abstract Poster Presenter: Susan Manzi, MD, MPH – Allegheny Health Network
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1546: Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
    Location: Hall F1
    Abstract Poster Presenter: Urvi Zala, MD (she/her/hers) – Loyola Medicine MacNeal Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1547: Anifrolumab in Systemic Lupus Erythematosus with Renal Involvement: National Multicenter Registry in Clinical Practice
    Location: Hall F1
    Abstract Poster Presenter: Vanesa Calvo Río, MD – Hospital Universitario Marqués de Valdecilla, Immunopathology group, IDIVAL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1548: Anifrolumab in Systemic Lupus Erythematosus. Spanish Multicenter Registry in Clinical Practice
    Location: Hall F1
    Abstract Poster Presenter: Vanesa Calvo Río, MD – Hospital Universitario Marqués de Valdecilla, Immunopathology group, IDIVAL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1549: Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
    Location: Hall F1
    Abstract Poster Presenter: Vasileios Kyttaris, MD, PhD – BIDMC
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1550: Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
    Location: Hall F1
    Abstract Poster Presenter: Virginia Carrizo Abarza, Sr, MD – Toronto Western Hospital - University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1551: Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
    Location: Hall F1
    Abstract Poster Presenter: Zahi Touma, MD, PhD – University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
    Location: Hall F1
    Abstract Poster Presenter: Zahi Touma, MD, PhD – University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1516: The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
    Location: Hall F1
    Abstract Poster Presenter: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine
  • Monday, Oct 27th
    1:00 PM - 2:00 PM Central Time
    27M50: Great Debate: Corticosteroids in Pediatric SLE: Slay or Stay
    Location: W471B
    Moderator: Joyce Hui-Yuen, MD, MS – North Shore LIJ Health System
    Moderator: Ekemini Ogbu, MD, MSc – Cincinnati Children's Hospital Medical Center
    Session Coordinator: Ekemini Ogbu, MD, MSc – Cincinnati Children's Hospital Medical Center
    Session Coordinator: Joyce Hui-Yuen, MD, MS – North Shore LIJ Health System
     CE: 1.00
  • Monday, Oct 27th
    1:00 PM - 1:30 PM Central Time
    Discontinuing Corticosteroids in Pediatric Lupus
    Location: W471B
    Speaker: Emily von Scheven, MD – University of California, San Francisco
  • Monday, Oct 27th
    1:30 PM - 2:00 PM Central Time
    Continuing Corticosteroids in Pediatric Lupus
    Location: W471B
    Speaker: Hermine Brunner, MD, MSc, MBA – Cincinnati Children's Hospital Medical Center
  • Monday, Oct 27th
    1:00 PM - 2:30 PM Central Time
    27M46: Bench to Bedside in the Diagnosis and Treatment of Lupus Nephritis
    Location: W196A-C
    Moderator: Lisa Sammaritano, MD – Hospital for Special Surgery
    Moderator: May Choi, MD, FRCPC, MPH – University of Calgary
    Session Coordinator: Anca Askanase, MD, MPH – Columbia University Medical Center
     CE: 1.50
  • Monday, Oct 27th
    1:00 PM - 1:30 PM Central Time
    Applying Learnings from the AMP Program into the Clinic
    Location: W196A-C
    Speaker: Andrea Fava, MD – Johns Hopkins University
  • Monday, Oct 27th
    1:30 PM - 2:00 PM Central Time
    Applying the Guideline to the Treatment of Refractory LN
    Location: W196A-C
    Speaker: Maria Dall'Era, MD – UCSF
  • Monday, Oct 27th
    2:00 PM - 2:30 PM Central Time
    Applying the Guideline to the Treatment of LN for Newly Available Treatments
    Location: W196A-C
    Speaker: Anca Askanase, MD, MPH – Columbia University Medical Center
  • Monday, Oct 27th
    3:00 PM - 4:30 PM Central Time
    27M61: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality
    Location: S102
    Abstract Moderator: Fotios Koumpouras, MD – Yale School of Medicine
    Abstract Moderator: Zahi Touma, MD, PhD – University of Toronto
     CE: 0.00
  • Monday, Oct 27th
    3:00 PM - 4:30 PM Central Time
    27M66: Abstracts: ARP I: Multidimensional Influences on Health in SLE
    Location: W192A-C
    Abstract Moderator: Yen Chen, PhD (she/her/hers) – University of Michigan
    Abstract Moderator: Jessica Widdifield, PhD – Sunnybrook Research Institute
     CE: 0.00
  • Monday, Oct 27th
    3:00 PM - 3:15 PM Central Time
    1686: The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
    Location: W192A-C
    Presenting Author: Patti Katz, PhD – UCSF
  • Monday, Oct 27th
    3:00 PM - 3:15 PM Central Time
    1716: The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
    Location: S102
    Presenting Author: Laura Ross, MBBS PhD FRACP – The University of Melbourne
  • Monday, Oct 27th
    3:15 PM - 3:30 PM Central Time
    1687: Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
    Location: W192A-C
    Presenting Author: Hector Martinez-Espinosa, -None- (he/him/his) – Universidad Autonoma de Nuevo Leon
  • Monday, Oct 27th
    3:15 PM - 3:30 PM Central Time
    1717: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
    Location: S102
    Presenting Author: Benny Rashuamán-Conche, MD (he/him/his) – Hospital Guillermo Almenara Irigoyen.
  • Monday, Oct 27th
    3:30 PM - 3:45 PM Central Time
    1688: Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients
    Location: W192A-C
    Presenting Author: Akhila Veeravalli, MSc, BA (she/her/hers) – Self-Employed
  • Monday, Oct 27th
    3:30 PM - 3:45 PM Central Time
    1718: Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
    Location: S102
    Presenting Author: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Monday, Oct 27th
    3:45 PM - 4:00 PM Central Time
    1689: Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
    Location: W192A-C
    Presenting Author: Kimberly Cabrera, BS – Hospital for Special Surgery
  • Monday, Oct 27th
    3:45 PM - 4:00 PM Central Time
    1719: Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
    Location: S102
    Presenting Author: Rusudan Tskitishvili, MD – Virtua Health
  • Monday, Oct 27th
    4:00 PM - 4:15 PM Central Time
    1690: Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus
    Location: W192A-C
    Presenting Author: Jennifer Woo, PhD, MPH (she/her/hers) – NIEHS
  • Monday, Oct 27th
    4:00 PM - 4:15 PM Central Time
    1720: Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
    Location: S102
    Presenting Author: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
  • Monday, Oct 27th
    4:15 PM - 4:30 PM Central Time
    1691: Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
    Location: W192A-C
    Presenting Author: Andrea Gutierrez, BS – University of Texas Southwestern Medical School
  • Monday, Oct 27th
    4:15 PM - 4:30 PM Central Time
    1721: Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
    Location: S102
    Presenting Author: Mario Bautista - Vargas, Sr, MD – Mayo Clinic
  • Tuesday, Oct 28th
    10:00 AM - 11:30 AM Central Time
    28T14: Abstracts: Systemic Lupus Erythematosus – Animal Models
    Location: S105
    Abstract Moderator: Paul Hoover, MD, PhD – Brigham and Women's Hospital
    Abstract Moderator: Trine Jorgensen, PhD – Education, Cleveland Clinic Foundation
     CE: 0.00
  • Tuesday, Oct 28th
    10:00 AM - 10:15 AM Central Time
    1758: Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
    Location: S105
    Presenting Author: Grace Crossland, BS – Dartmouth College
  • Tuesday, Oct 28th
    10:15 AM - 10:30 AM Central Time
    1759: Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
    Location: S105
    Presenting Author: Abhimanyu Amarnani, MD, PhD – New York University Grossman School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 10:45 AM Central Time
    1760: Targeting the Female-biased Factor VGLL3 in Cutaneous and Systemic Lupus
    Location: S105
    Presenting Author: Vincent van Drongelen, PhD, MSc – University of Michigan - Michigan Medicine
  • Tuesday, Oct 28th
    10:45 AM - 11:00 AM Central Time
    1761: The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
    Location: S105
    Presenting Author: Juan Liang, DrPH – Gempharmatech
  • Tuesday, Oct 28th
    11:15 AM - 11:30 AM Central Time
    1763: Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses
    Location: S105
    Presenting Author: Paul Hoover, MD, PhD – Brigham and Women's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Systemic Lupus Erythematosus – Treatment Poster III
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1830: Single-Cell and Spatial Profiling Reveal Proinflammatory and Profibrotic Fibroblast-Macrophage Niches in Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Chirag Raparia, PhD, MS, BS (he/him/his) – Donald and Barbara Zucker School of Medicine At Hofstra/Northwell
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1831: Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
    Location: Hall F1
    Abstract Poster Presenter: Christian Wright, BS – University of Oklahoma Health Sciences Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1832: Time-to-Event Analysis of Statin Use and Thrombotic Risk in Patients with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
    Location: Hall F1
    Abstract Poster Presenter: Christine Lenchur, DO – Icahn School of Medicine at Mount Sinai
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1833: DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
    Location: Hall F1
    Abstract Poster Presenter: DONG ZHANG, PhD (he/him/his) – D2M Biotherapeutics, Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1834: Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
    Location: Hall F1
    Abstract Poster Presenter: Eva Galindo Calvillo, MD (she/her/hers) – Hospital Universitario Dr. Jose Eleuterio Gonzalez
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1835: Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis
    Location: Hall F1
    Abstract Poster Presenter: Giulio Forte, n/a – Università della Campania Luigi Vanvitelli
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1836: Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Jennifer Balderas Miranda, MD, PhD (she/her/hers) – Universidad Nacional Autónoma de México
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1837: Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
    Location: Hall F1
    Abstract Poster Presenter: John D. Mountz, MD, PhD – University Alabama Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1838: Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
    Location: Hall F1
    Abstract Poster Presenter: Jolien Suurmond, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1839: Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
    Location: Hall F1
    Abstract Poster Presenter: Loqmane seridi, PhD – J&J
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1840: Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
    Location: Hall F1
    Abstract Poster Presenter: Lorenzo Beretta, MD – Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1841: Differential metabolomic signatures along lupus nephritis spectrum
    Location: Hall F1
    Abstract Poster Presenter: Mariana Jiménez Tirado, MD (she/her/hers) – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1842: Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
    Location: Hall F1
    Abstract Poster Presenter: Melissa Munroe, MD, PhD (she/her/hers) – Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1843: Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Norio Hanata, M.D., Ph.D. – Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1844: Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Paul Hoover, MD, PhD – Brigham and Women's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1845: Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
    Location: Hall F1
    Abstract Poster Presenter: Rodolfo Martinez-Canales, MD (he/him/his) – Facultad de Medicina y Hospital Universitario UANL
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1846: Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
    Location: Hall F1
    Abstract Poster Presenter: Roopa Madhu, PhD – Brigham and Women's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1847: Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
    Location: Hall F1
    Abstract Poster Presenter: Sarah McCuaig, MD, PhD (she/her/hers) – Children's Hospital of Philadelphia
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1848: DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
    Location: Hall F1
    Abstract Poster Presenter: Shigeko Uryu, MSc – Daiichisankyo Co.,Ltd.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1849: Time-course RNA sequencing analysis of longitudinal peripheral blood samples to elucidate the factors determining treatment resistance in systemic lupus erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Shuji Sumitomo, MD, PhD (he/him/his) – Kobe City Medical Center General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1850: First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
    Location: Hall F1
    Abstract Poster Presenter: Tayte Stephens, BS – University of Oklahoma Health Science Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1851: Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
    Location: Hall F1
    Abstract Poster Presenter: Tomás Cerdó, PhD – Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1852: Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
    Location: Hall F1
    Abstract Poster Presenter: Victoria Werth, MD – University of Pennsylvania
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1853: SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
    Location: Hall F1
    Abstract Poster Presenter: Yevgeniya Gartshteyn, MD, MS – Columbia University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1854: Resting-State Functional Magnetic Resonance Imaging Analysis Revealed Altered Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Yujie Song, MB – Hokkaido University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2377: Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2378: Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
    Location: Hall F1
    Abstract Poster Presenter: Alvaro Oyarce-Calderón, Sr, MD (he/him/his) – Hospital Nacional Guillermo Almenara Irigoyen
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2379: Predicting Type 1 and Type 2 SLE Activity Using the LupusPRO
    Location: Hall F1
    Abstract Poster Presenter: Amanda Eudy, PhD – Duke University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2380: Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
    Location: Hall F1
    Abstract Poster Presenter: April Barnado, MD, MSc – Vanderbilt University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2381: Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Angela Lu, BS – Albert Einstein College of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2382: Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Ansaam Daoud, MD – Case Western Reserve University/University Hospitals
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2383: The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
    Location: Hall F1
    Abstract Poster Presenter: Benny Rashuamán-Conche, MD (he/him/his) – Hospital Guillermo Almenara Irigoyen.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2384: Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
    Location: Hall F1
    Abstract Poster Presenter: Bernie Rubin – Progentec Diagnostics
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2385: The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Billy Kim, MD – Hospital for Special Surgery
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2386: anti-trim72 Auto-antibodies in Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
    Location: Hall F1
    Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2387: Lupus Damage Index Revision – Item Generation and Reduction Phases
    Location: Hall F1
    Abstract Poster Presenter: Burak Kundakci, PhD, MSc – University of Manchester
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2388: Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
    Location: Hall F1
    Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2389: A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Chelsea Guan, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2390: SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight
    Location: Hall F1
    Abstract Poster Presenter: Dag Leonard, MD, PhD – Uppsala University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2391: Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
    Location: Hall F1
    Abstract Poster Presenter: Damira Sereda, MD – Stamford
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2392: Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
    Location: Hall F1
    Abstract Poster Presenter: Daniyal Nadeem, MD – Louisiana state university health shreveport
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2393: Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
    Location: Hall F1
    Abstract Poster Presenter: Ed Vital, MD – University of Leeds
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2394: Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
    Location: Hall F1
    Abstract Poster Presenter: Emily Cosentino, MD – Icahn School of Medicine at Mount Sinai
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2395: Analysis of Histopathological Changes in the Placenta of Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Evandro Klumb, n/a (he/him/his) – UERJ - Universidade do Estado do Rio de Janeiro
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2396: A Machine Learning Algorithm Based on a 15-autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
    Location: Hall F1
    Abstract Poster Presenter: Gerber Gomez, MD, MSc (he/him/his) – AliveDx Suisse SA
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2397: Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
    Location: Hall F1
    Abstract Poster Presenter: Gerber Gomez, MD, MSc (he/him/his) – AliveDx Suisse SA
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2398: Analytical Performance of the hep-2 Substrate Diagnostic Kit for ANA as an Initial Step in the Evaluation of a Novel Fully Automated IFA Analyzer in a Laboratory in England
    Location: Hall F1
    Abstract Poster Presenter: Gerber Gomez, MD, MSc (he/him/his) – AliveDx Suisse SA
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2399: Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
    Location: Hall F1
    Abstract Poster Presenter: Gregg Silverman, MD – NYU Grossman School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2400: Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
    Location: Hall F1
    Abstract Poster Presenter: Henrik Zachar Langkilde, MD (he/him/his) – Department of Rheumatology, Odense University Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2401: Associations Between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2402: High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
    Location: Hall F1
    Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2403: Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
    Location: Hall F1
    Abstract Poster Presenter: Jaime Flores Gouyonnet, MD – Mayo Clinic
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2404: Clinical features of Elderly-onset Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Jessica Dai, BS – New York University Grossman School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2405: Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Joan Manuel Dapeña, Sr, MD (he/him/his) – Sanatorio Dr. Julio Mendez
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2406: Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
    Location: Hall F1
    Abstract Poster Presenter: Jorge Juan Fragio Gil, MD;PhD (he/him/his) – Hospital General Universitario
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2407: Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Jorge Juan Fragio Gil, MD;PhD (he/him/his) – Hospital General Universitario
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2408: Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population
    Location: Hall F1
    Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2409: Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
    Location: Hall F1
    Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2410: Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Liyoung Kim, MD (she/her/hers) – Boston Children's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2411: The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
    Location: Hall F1
    Abstract Poster Presenter: Luca Mazzoleni, -None- – University of Brescia
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2412: Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
    Location: Hall F1
    Abstract Poster Presenter: Maria Emilia Romero Noboa, MD – University of Alabama at Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2413: Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Mariana Gonzalez-Trevino, MD – Vanderbilt University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2414: Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
    Location: Hall F1
    Abstract Poster Presenter: May Choi, MD, FRCPC, MPH – University of Calgary
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2415: Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online
    Location: Hall F1
    Abstract Poster Presenter: Meenakshi Jolly, MD – Rush University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2416: Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
    Location: Hall F1
    Abstract Poster Presenter: Megan Barber, MD, PhD – University of Calgary
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2417: Anti-dense Fine Speckled 70 Antibodies in Undefined Disease, Systemic Autoimmune Rheumatic Diseases and Controls
    Location: Hall F1
    Abstract Poster Presenter: Meghna Gavali, MBBS, MD (she/her/hers) – Nizam's institute of medical sciences ,Hyderabad
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2418: ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
    Location: Hall F1
    Abstract Poster Presenter: Mehrnaz Gharaee-Kermani, DVM, MPH, PhD – University of Michigan
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2419: Dried Blood Spots for Remote ANA and Autoantibody Screening
    Location: Hall F1
    Abstract Poster Presenter: Feng Yun Li, MD – University of Calgary
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2420: In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)
    Location: Hall F1
    Abstract Poster Presenter: Nattanicha Chaisrimaneepan, MD – Texas Tech University Health Sciences Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2421: Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
    Location: Hall F1
    Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2422: Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Oihane Ibarguengoitia-Barrena, MD – Galdakao-Usansolo University Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2423: Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
    Location: Hall F1
    Abstract Poster Presenter: Rebecca Hetrick, MD, MS – Indiana University School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2425: Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
    Location: Hall F1
    Abstract Poster Presenter: Roberto Caricchio, MD – University of Massachusetts Chan Medical School
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2426: Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Sarah Lieber, MD, MS – Hospital for Special Surgery
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2427: Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
    Location: Hall F1
    Abstract Poster Presenter: Sepehr Taghavi, MSc – Exagen Inc
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2428: Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
    Location: Hall F1
    Abstract Poster Presenter: Shae Chambers, BA – University of Pennsylvania
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2429: mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
    Location: Hall F1
    Abstract Poster Presenter: Shanthini Kasturi, MD;MS (she/her/hers) – Tufts Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2430: Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Steven Bieser, MD – Northwestern University Feinberg School of Medicine, NMH hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2431: Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2432: Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Valerie Lewis, Ph.D. (she/her/hers) – Oklahoma Medical Research Foundation
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2433: The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
    Location: Hall F1
    Abstract Poster Presenter: Vasileios Kyttaris, MD, PhD – BIDMC
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2434: Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
    Location: Hall F1
    Abstract Poster Presenter: Vasileios Kyttaris, MD, PhD – BIDMC
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2436: Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
    Location: Hall F1
    Abstract Poster Presenter: Yoo Jin Kim, MD, MS – Duke University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2437: Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
    Location: Hall F1
    Abstract Poster Presenter: Aaron Smith, MD, MS – University of North Carolina
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2438: SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Ahmad Alomari, MD – UCF / North Florida Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2439: Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
    Location: Hall F1
    Abstract Poster Presenter: Ahmad Alomari, MD – UCF / North Florida Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2440: Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
    Location: Hall F1
    Abstract Poster Presenter: Bruno Flamion, MD, PhD (he/him/his) – Viatris Innovation GmbH
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2441: Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
    Location: Hall F1
    Abstract Poster Presenter: Cynthia Aranow, MD – Feinstein Institutes for Medical Research
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2442: Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
    Location: Hall F1
    Abstract Poster Presenter: Danae-Mona Nöthling, MD – University Clinic Erlangen, Germany
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2443: WITHDRAWN
    Location: Hall F1
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2444: Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
    Location: Hall F1
    Abstract Poster Presenter: Emily Gutowski, MD – NYU
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2445: Achievement of Treat to Target Measures with Upadacitinib in Patients with Systemic Lupus Erythematosus: Phase 2 Randomized Sleek Clinical Trial Results
    Location: Hall F1
    Abstract Poster Presenter: Eric Morand, MD, PhD – Monash University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2446: Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Reports
    Location: Hall F1
    Abstract Poster Presenter: Eugenia Chock, MD – Yale School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2447: Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
    Location: Hall F1
    Abstract Poster Presenter: Fumin Qi, n/a – Tianjin Medical University General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2448: Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Haiting Wang, MD, PhD (she/her/hers) – Renji Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2449: Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren's Syndrome: An Analysis Using Japanese Inpatient Database
    Location: Hall F1
    Abstract Poster Presenter: Hiroshi Shiba, MD – Suwa central hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2450: Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
    Location: Hall F1
    Abstract Poster Presenter: Irene Carrión-Barberà, MD, PhD – University of Washington
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2451: Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: J. Michelle Kahlenberg, MD, PhD – University of Michigan
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2452: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
    Location: Hall F1
    Abstract Poster Presenter: Jan Davidson-Moncada, PhD, MBBS – Bioheng
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2453: Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
    Location: Hall F1
    Abstract Poster Presenter: Jeff Ellis, PharmD, MS – GSK
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2454: Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
    Location: Hall F1
    Abstract Poster Presenter: Trever Greene, PhD – Fate Therapeutics
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2455: Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
    Location: Hall F1
    Abstract Poster Presenter: Justin Arnold, BA (he/him/his) – Northwestern Feinberg School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2456: Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
    Location: Hall F1
    Abstract Poster Presenter: Karen Worley, PhD, MS – GSK, Global Real-World Evidence & Health Outcomes Research
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2457: Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Kenza EL OUAZZANI ECH CHAHDI, BS – Bordeaux University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2458: Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
    Location: Hall F1
    Abstract Poster Presenter: Maria Leandro, MD,PhD,FRCP – UCL/UCLH
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2459: Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
    Location: Hall F1
    Abstract Poster Presenter: Milena Delai, MD – Beth Israel Deaconess Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2460: Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
    Location: Hall F1
    Abstract Poster Presenter: Pablo Martinez Calabuig, Sr, MD – HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN/ Escuela de doctoradoUniversidad Católica de Valencia San Vicente Mártir, Valencia, Spain
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2461: Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
    Location: Hall F1
    Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2462: Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
    Location: Hall F1
    Abstract Poster Presenter: Pooja Patel, DO – Ann and Robert H. Lurie Children's Hospital of Chicago
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2463: Allogenic Anti- CD19 CAR-T Cells Induce Remission in Refractory Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Qian Tan, MD, PhD – BRL Medicine Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2464: IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
    Location: Hall F1
    Abstract Poster Presenter: Qian Zheng, PhD – ImmuneCare Biopharmaceuticals(Shanghai) Co., LTD
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2465: CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
    Location: Hall F1
    Abstract Poster Presenter: Qiong Fu, MD (she/her/hers) – Renji Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2466: Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Richard Furie, MD – Northwell
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2467: Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Richard A. Furie, MD – Northwell
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2468: RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
    Location: Hall F1
    Abstract Poster Presenter: Saira Sheikh, MD – University of North Carolina at Chapel Hill
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2469: Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
    Location: Hall F1
    Abstract Poster Presenter: Wen-Nan Huang, MD, PhD. (he/him/his) – Taichung Veterans General Hospital
  • Tuesday, Oct 28th
    1:00 PM - 2:00 PM Central Time
    28T41: Tissue Is the Issue: How Kidney Physiology Impacts Immunity
    Location: W475A-B
    Moderator: Theresa Lu, MD;PhD – Hospital for Special Surgery
    Moderator: Jeremy Tilstra, MD, PhD – University of Pittsburgh
    Session Coordinator: Jeremy Tilstra, MD, PhD – University of Pittsburgh
     CE: 1.00
  • Tuesday, Oct 28th
    1:00 PM - 1:30 PM Central Time
    Principal Immune Cell Trajectories in Human Lupus Nephritis
    Location: W475A-B
    Speaker: Marcus Clark, MD – University of Chicago
  • Tuesday, Oct 28th
    1:30 PM - 2:00 PM Central Time
    Trafficking of Immune Cells into the Kidney in SLE
    Location: W475A-B
    Speaker: Joe Craft, MD – Yale University
  • Tuesday, Oct 28th
    1:00 PM - 2:30 PM Central Time
    28T31: Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis
    Location: S103
    Abstract Moderator: Andras Perl, MD, PhD – SUNY
    Abstract Moderator: Melissa Cunningham, MD, PhD – Medical University of South Carolina
     CE: 0.00
  • Tuesday, Oct 28th
    1:00 PM - 1:15 PM Central Time
    2597: Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups
    Location: S103
    Presenting Author: Yang Wu, MD, PhD – University of Washington; Chinese Academy of Medical Sciences & Peking Union Medical College
  • Tuesday, Oct 28th
    1:15 PM - 1:30 PM Central Time
    2598: Keratinocyte-Secreted Leukemia Inhibitory Factor Counteracts Type I IFN-Induced Antigen-Presenting Phenotype in Melanocytes: Utility in Cutaneous Lupus Skin
    Location: S103
    Presenting Author: Rezvan Moallemian, PhD, DVM – University of Michigan
  • Tuesday, Oct 28th
    1:30 PM - 1:45 PM Central Time
    2599: Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
    Location: S103
    Presenting Author: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
  • Tuesday, Oct 28th
    1:45 PM - 2:00 PM Central Time
    2600: Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
    Location: S103
    Presenting Author: Nicholas Sugiarto, BA (he/him/his) – Harvard Medical School
  • Tuesday, Oct 28th
    2:00 PM - 2:15 PM Central Time
    2601: Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
    Location: S103
    Presenting Author: Antonios Psarras, MD, PhD, MSc, MRCP – University of Oxford
  • Tuesday, Oct 28th
    2:15 PM - 2:30 PM Central Time
    2602: Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
    Location: S103
    Presenting Author: Masahiro Nakano, PhD,MD – RIKEN Center for Integrative Medical Sciences
  • Tuesday, Oct 28th
    2:30 PM - 4:00 PM Central Time
    28T52: Prevention Is the Best Medicine: Updates for Rheumatoid Arthritis and Lupus
    Location: W196A-C
    Moderator: Liam O'Neil, MD, MHS – University of Manitoba
    Moderator: Yevgeniya Gartshteyn, MD, MS – Columbia University Medical Center
    Session Coordinator: Janet Pope, MD, FRCPC, MPH – University of Western Ontario
    Session Coordinator: May Choi, MD, FRCPC, MPH – University of Calgary
     CE: 1.50
  • Tuesday, Oct 28th
    2:30 PM - 3:00 PM Central Time
    Identifying Who Is at Risk of Developing SLE and RA
    Location: W196A-C
    Speaker: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
  • Tuesday, Oct 28th
    3:00 PM - 3:30 PM Central Time
    Rheumatoid Arthritis Prevention: From the Mouse to the Human
    Location: W196A-C
    Speaker: Kevin Deane, MD, PhD – University of Colorado Denver Anschutz Medical Campus
  • Tuesday, Oct 28th
    3:30 PM - 4:00 PM Central Time
    Can Lupus Be Prevented? Updates from the SMILE Trial
    Location: W196A-C
    Speaker: David Karp, MD, PhD, MACR – UT Southwestern Medical Center
  • Wednesday, Oct 29th
    9:30 AM - 11:00 AM Central Time
    29W06: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III
    Location: W192A-C
    Abstract Moderator: Cynthia Aranow, MD – Feinstein Institutes for Medical Research
    Abstract Moderator: Ernest Vina, MD, MSc – University of Arizona
     CE: 0.00
  • Wednesday, Oct 29th
    9:30 AM - 9:45 AM Central Time
    2645: Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
    Location: W192A-C
    Presenting Author: Peter Izmirly, MD – New York University Grossman School of Medicine
  • Wednesday, Oct 29th
    9:45 AM - 10:00 AM Central Time
    2646: DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
    Location: W192A-C
    Presenting Author: Meghan Nelson, DO – National Institutes of Health
  • Wednesday, Oct 29th
    10:00 AM - 10:15 AM Central Time
    2647: Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
    Location: W192A-C
    Presenting Author: Dag Leonard, MD, PhD – Uppsala University
  • Wednesday, Oct 29th
    10:15 AM - 10:30 AM Central Time
    2648: Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares
    Location: W192A-C
    Presenting Author: Lorenzo Beretta, MD – Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano
  • Wednesday, Oct 29th
    10:30 AM - 10:45 AM Central Time
    2649: Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
    Location: W192A-C
    Presenting Author: Melissa Munroe, MD, PhD (she/her/hers) – Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc.
  • Wednesday, Oct 29th
    10:45 AM - 11:00 AM Central Time
    2650: LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
    Location: W192A-C
    Presenting Author: Alberto Nordmann-Gomes, BS – Columbia University Irving Medical Center
  • Wednesday, Oct 29th
    11:30 AM - 1:00 PM Central Time
    29W14: Abstracts: Systemic Lupus Erythematosus – Treatment II
    Location: W375C
    Abstract Moderator: Graciela Alarcón, MD, MPH (she/her/hers) – The University of Alabama at Birmingham
    Abstract Moderator: David Pisetsky, MD, PhD – Duke University Medical Center
     CE: 0.00
  • Wednesday, Oct 29th
    11:30 AM - 11:45 AM Central Time
    2697: A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-maintenance Treatment for Class III/IV±V Lupus Nephritis
    Location: W375C
    Presenting Author: Sandra Navarra, md, MD – University of Santo Tomas
  • Wednesday, Oct 29th
    11:45 AM - 12:00 PM Central Time
    2694: Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
    Location: W375C
    Presenting Author: Amit Saxena, MD, MSc – NYU Grossman School of Medicine
  • Wednesday, Oct 29th
    12:00 PM - 12:15 PM Central Time
    2695: B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
    Location: W375C
    Presenting Author: Carlo Tur, MD – Universitätsklinikum Erlangen - FAU Erlangen - Nürnberg
  • Wednesday, Oct 29th
    12:15 PM - 12:30 PM Central Time
    2696: Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
    Location: W375C
    Presenting Author: Eric Morand, MD, PhD – Monash University
  • Wednesday, Oct 29th
    12:30 PM - 12:45 PM Central Time
    2693: CAR T-cell Therapy in SLE: A Systematic Review
    Location: W375C
    Presenting Author: Alberto Nordmann-Gomes, BS – Columbia University Irving Medical Center
  • Wednesday, Oct 29th
    12:45 PM - 1:00 PM Central Time
    2698: Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
    Location: W375C
    Presenting Author: YUN KYU KIM, MD – Seoul National University